TrialClinical pharmacology and therapeutics2020

Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis.

Ahmed Nader et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.